INTRODUCTION
Glucocorticoids have occupied a central role in the treatment of hematological malignancies for over 50 years, due to their ability to induce apoptosis in normal and neoplastic lymphoid cells. 1 Glucocorticoid therapy plays a crucial role in the treatment of childhood acute lymphoblastic leukemia (ALL), and patient response to treatment is an important determinant of clinical outcome. 2 Prolonged use can result in the development of resistance in leukemia cells, although the mechanisms by which resistance develops remain poorly defined. 3, 4 Molecular studies, largely using cultured cells, have established several basic facts about the action of glucocorticoids on leukemia cells, although the pathway remains incompletely defined.
Glucocorticoids are steroid hormones that act on their target cell by signaling through a specific, cytosolic glucocorticoid receptor (GR) to induce apoptosis. 5 The GR is a member of the nuclear receptor family of ligand-dependent transcription factors, and exists in two major forms, α and β, and the β may exert dominant negative effects over the α. 6 A large number of studies using patient biopsy material have attempted to establish a relationship between cellular GR content and glucocorticoid sensitivity, and while a low number of receptors is frequently associated with resistance, high receptor number does not necessarily predict sensitivity. [7] [8] [9] Upon ligand binding, the GR dissociates from the large protein complex that maintains it in an inactive conformation in the cytoplasm. 10,11 Nuclear translocation and activation of the GR results in: (i) transactivation of target genes via direct interaction with specific palindromic DNA sequences known as glucocorticoid response elements (GREs); 12 (ii) repression of gene activation via interaction with DNA sequences called negative GREs; 13 (iii) enhancement or repression of gene transcription via interaction with composite GREs, which specify binding sites for the GR and one or more non-receptor factors; 12,14 and (iv) repression of gene activation via DNA-independent interactions between the GR and other transcription factor complexes such as AP-1 and NF-κB.
12, [15] [16] [17] This complex protein interplay results in activation or repression of gene transcription, leading to caspase and endonuclease activation, and apoptosis. 3, 12 However, it is still unclear which specific only.
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The Bcl-2 family of proteins is critical in regulating apoptosis induced by numerous cellular stresses, including exposure to glucocorticoids, which proceeds via breakdown of mitochondrial transmembrane potential and release of pro-apoptotic molecules into the cytosol, the "intrinsic" pathway.
12, 18 Bcl-2 family proteins possess either pro-or anti-apoptotic function, and are related through conserved sequence motifs, Bcl-2 homology (BH) domains. Bcl-2 family members related by a single region of homology, BH3-only, are pro-apoptotic via binding to and antagonizing antiapoptotic members such as Bcl-2, Bcl-x L , Bcl-w, and, to a lesser extent, Mcl-1 and A1. 19 The only
Bcl-2 family member consistently shown in microarray analysis of gene expression studies to be up-regulated by glucocorticoids in lymphoid cells is the BH3-only protein, Bim (Bcl-2L11).
20-22
Alternative splicing of bim mRNA gives rise to three isoforms, Bim S , Bim L and Bim EL , all of which potently induce apoptosis, with Bim S being the most cytotoxic. 19 The larger isoforms, Bim L and Bim EL , contain additional regulatory regions that interact with the dynein light chain LC8, which modulates their pro-apoptotic activity. 19 The study of leukemia cell lines has shown glucocorticoid resistance to be almost invariably associated with receptor defects leading to impaired ligand-receptor interactions. [23] [24] [25] [26] [27] [28] However, such mechanisms are rarely observed in primary patient material, 26-31 the only report being the original biopsy material from which the CEM cell line was derived. 32 To date, the apparent discrepancy between clinical findings and those using cell line model systems remains unexplained.
We have previously shown that the in vivo and in vitro responses to the glucocorticoid, dexamethasone, of childhood ALL biopsy specimens established as xenografts in nonobese diabetic/severe combined immunodeficient (NOD/SCID) mice closely reflect the clinical outcome of the patients from whom they were derived. 33 Consequently, mechanisms governing the differential glucocorticoid responses exhibited by these xenografts are likely to be highly relevant to the clinical disease. In this study, we show that dexamethasone resistance in a subset of xenografts only.
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only.
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MATERIALS AND METHODS

In vitro culture and drug treatments
The development, characterization, and in vivo and in vitro dexamethasone responses of a series of childhood ALL xenografts derived from patient biopsies have been described previously. 33 Oaks, CA), penicillin (100 U/mL), streptomycin (100 µg/mL) and L-glutamine (2 mM) (QBSF-60/F). Viability was determined by the exclusion of 0.2% trypan blue. For drug treatments, cells were equilibrated at 37ºC, 5% CO 2 , for at least 4 h prior to the addition of dexamethasone to a final concentration of 1 µM in QBSF-60/F. An equivalent volume of media only was added to control cells. Cells were harvested at the appropriate time points by centrifugation at 490g for 10 min, aspirating media, and washing cells twice with sterile calcium-and magnesium-free phosphate-buffered saline (PBS).
The human T-lineage ALL cell line, CEM-WT, and its dexamethasone-resistant subline, MTX-R3, 35 were maintained as static suspensions at 37ºC, 5% CO 2 , in RPMI-1640 medium (Invitrogen Life Technologies, Gaithersburg, MD) supplemented with 10% fetal bovine serum (FBS, Invitrogen Life Technologies), penicillin (100 U/mL), streptomycin (100 µg/mL) and L-glutamine (2 mM) (complete RPMI). All procedures using CEM cell lines have been described previously.
35
In vitro cytotoxicity assays
In vitro drug sensitivity was assessed using the colorimetric methyl-thiazolyl-tetrazolium (MTT) assay, which measures a combination of inhibition of proliferation and cell death. One day prior to drug treatment, xenograft cells were retrieved from cryostorage, resuspended in QBSF-60/F at a cell concentration previously optimized for each xenograft (2-5x10 6 
Radioligand binding assays
Specific glucocorticoid receptor binding sites were measured in whole cell binding assays as we have previously described. 35 Xenograft cells were resuspended in QBSF-60/F media at a final concentration of 5x10 6 cells/mL. Aliquots of this cell suspension (980 µL) were allowed to equilibrate at 37ºC for 1 h. Cells were then incubated an additional 1 h at 37ºC with 10 µL of Data shown are cumulative from two independent experiments. The number of binding sites per cell (B max ) and the affinity of the receptors for dexamethasone (K D ) were determined using GraphPad Prism (Version 4.00, GraphPad Software, Inc., San Diego, CA).
Immunofluorescence microscopy
Xenograft cells were resuspended in QBSF-60/F at a density of 5x10 5 cells/mL, and allowed to equilibrate at 37ºC, 5% CO 2 , for 2 h. Dexamethasone was diluted in QBSF-60/F media and added 
Apoptosis assays
Loss of mitochondrial transmembrane potential was assessed using the cationic dye JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethyl-benzimidazolylcarbocyanine iodide, Molecular Probes, Inc., Eugene, OR). Following dexamethasone treatment (1 µM up to 24 h) cells were harvested and incubated in only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From PBS containing 0.5 g/mL JC-1 for 10 min at 37°C. Cells were washed twice in 2 mL of PBS and the proportion of cells appearing in the viable region by forward-and side-scatter characteristics that exhibited a shift from red fluorescent J-aggregates to green fluorescent JC-1 monomers was determined using a FACSCalibur flow cytometer (BD Immunocytometry Systems, San Jose, CA).
The proportion of cells with active caspase-3 or caspase-7 (caspase-3/7) following treatment with dexamethasone (1 µM up to 48 h) was assessed by flow cytometry using the cell-permeable inhibitor, carboxyfluorescein-labeled fluoromethyl ketone (FAM-DEVD-FMK, CaspaTag TM ,
Chemicon International, Inc., Temecula, CA), according to the manufacturer's instructions.
Statistical comparisons
Quantitative variables were compared using the nonparametric Mann-Whitney U test (GraphPad Prism, Version 4.00; GraphPad Software, San Diego, CA). The level of significance was set to 0.05.
RESULTS
Sensitivity of childhood ALL xenograft cells to dexamethasone in vitro
We have previously described the development, characterization, and in vivo and in vitro dexamethasone responses of a series of childhood ALL xenografts established in NOD/SCID mice. 33, 34 The relevant disease-specific details of the patients from whom the xenografts were derived are shown in Table 1 . In order to study glucocorticoid resistance mechanisms in these xenografts, their responses to dexamethasone were compared using the MTT colorimetric assay. Table 1 , and indicate that a subset of 6 xenografts were highly inherently resistant to dexamethasone, with IC 50 values > 10 µM compared to 20-30 nM for ALL-8 and -17, and < 10 nM for the most sensitive xenografts (ALL-3, -11 and -16). The difference between the most resistant and sensitive xenografts represents >1,000-fold level of resistance. Cell viability by MTT assay showed an excellent correlation with our previously documented flow cytometric enumeration of viable cells at 10 nM (r = 0.87; P = 0.0004), 100 nM (r = 0.87; P = 0.0006) and 1 µM (r = 0.84; P = 0.0012) dexamethasone for all 11 xenografts. 33 The IC 50 values for CEM-WT and MTX-R3 cells exposed to dexamethasone for 72 h have previously been reported to be 51 nM and > 1 mM, respectively.
35
GR protein expression and functionality in xenograft cells
To determine whether resistance to dexamethasone correlated with down-regulation of GR expression, basal levels of GR protein were compared between xenografts by immunoblot analysis of whole cell lysates. Figure 2A , which shows a representative immunoblot and cumulative only.
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CEM-WT and MTX-R3 cell lines were used as controls, as the MTX-R3 cell line has previously been shown to express approximately 50% of GR protein compared with CEM-WT cells. 35 These results indicate that GR down-regulation does not account for the high level dexamethasone resistance observed in the B-lineage xenografts, ALL-2, -4, -7, -10, -18 and -19.
Previous reports have almost invariably associated glucocorticoid resistance in leukemia cell lines with receptor defects resulting in impaired ligand binding. [23] [24] [25] [26] [27] [28] Since analysis of GR protein expression alone could not exclude the presence of mutations in the GR that might affect ligandreceptor interactions in the resistant xenografts, radioligand binding studies were carried out.
Results from these studies indicate that only one xenograft, ALL-8, exhibited defective ligand binding ( Figure 2B and Table 2 ). The reduced number of specific binding sites per cell observed in ALL-8 (1 752 + 140) correlated with the reduced expression of receptor protein evident in the immunoblot analysis ( Figure 2A) . Similarly, the higher number of binding sites present in ALL-7 (15 794 + 543) corresponded with higher GR protein expression in this xenograft, although the same relationship was not apparent for ALL-18 (compare GR protein expression in Figure 2A with ligand binding characteristics in Figure 2B and Table 2 ). Overall, these studies revealed that, with the exception of the T-lineage ALL-8, defects at the level of receptor-ligand binding do not play a role in dexamethasone resistance of these xenografts. Radioligand binding assays using cells harvested from the spleens of animals engrafted with ALL-3, -7 and -19, and placed immediately into culture, confirmed that the high level dexamethasone resistance in ALL-7 and -19 was not due to defective ligand binding (P.S. Bachmann and R.B. Lock, unpublished observations).
Nuclear translocation of the GR following dexamethasone treatment
Since the glucocorticoid-induced apoptotic response is mRNA and protein synthesis-dependent, translocation of the receptor-ligand complex to the nucleus is a critical step in this pathway. 12 To determine whether dexamethasone resistance was associated with inhibition of GR nuclear translocation, GR protein was visualized by immunofluorescence labeling. Two glucocorticoidsensitive (ALL-3 and ALL-16) and two glucocorticoid-resistant (ALL-7 and ALL-19) xenografts were studied in detail. All four xenografts had been shown in the previous section to contain GR protein that was functional in binding ligand. The GR was localized predominantly to the cytoplasm in untreated cells (Figure 3 ). However, in the xenografts studied comparable amounts of GR protein co-localized with the DAPI stained nuclei at two and four hours of dexamethasone treatment, independent of sensitivity to dexamethasone.
To confirm these results using an independent technique, xenograft cells were separated into cytoplasmic and nuclear fractions which were subjected to immunoblot analysis. Figure 4 clearly shows that in untreated cells the GR was almost exclusively cytoplasmic in all xenografts.
However, following exposure to dexamethasone (1 µM, 5 h), translocation of the GR into the nucleus was comparable in all xenografts, regardless of their relative sensitivity to dexamethasone, including ALL-8 in which GR expression was down-regulated. Relevant protein controls for nuclear (topo I) and cytoplasmic (Bax) fractions, along with actin control, are also represented in For
resistant xenograft, ALL-4, was moderately attenuated (P = 0.05), while its induction in ALL-18 was comparable to the three highly sensitive xenografts (P = 0.86). While Bax and Bcl-2 protein expression remained unaffected by dexamethasone treatment (Figures 6 and 7) , the Bcl-2:Bax ratio appeared notably higher in ALL-18 than all other xenografts ( Figure 7A ).
Bim induction in cells from a dexamethasone-sensitive xenograft (ALL-16) exposed to dexamethasone was followed by loss of mitochondrial transmembrane potential and an increase in caspase-3/7 activity, all of which were suppressed in a resistant xenograft (ALL-19) (Figure 7C 
DISCUSSION
We have previously reported that the in vivo and in vitro responses to dexamethasone of childhood ALL xenografts established in NOD/SCID mice significantly correlated with the clinical outcome of the patients from who the xenografts were derived. 33, 34 In the present study, the relative in vitro sensitivities of xenografts to dexamethasone differed by >1,000-fold, with 5/6 highly resistant xenografts (IC 50 > 10 µM) being derived from patients at relapse or who have died from their disease. Therefore, it is highly likely that the mechanisms of resistance expressed by these xenografts will be relevant to that occurring in patients who present with glucocorticoid-resistant leukemia. Moreover, and in contrast with almost all studies using leukemia cell lines, no defects in receptor-ligand interactions or in dexamethasone-induced nuclear translocation of the GR were apparent in any of the BCP-ALL xenografts. Further investigation revealed that the resistance mechanisms were associated with, at least in part, the failure to induce expression of the proapoptotic Bcl-2 family member, Bim.
Studies that have attempted to associate the number of GR molecules per leukemia cell with clinical outcome have met with limited success. While low numbers of receptors per cell are generally associated with resistance, high receptor expression shows less of a correlation with sensitivity. 7, 9 Furthermore, the correlation between receptor content and response to glucocorticoids is generally poor. 8, 38 Evaluation of our panel of xenografts revealed no correlation between GR protein expression and sensitivity to dexamethasone. Only one xenograft, ALL-8, derived from a patient with T-lineage ALL at relapse, showed a significant deficit in GR expression when compared with other xenografts and the CEM-WT cell line.
Radioligand binding studies subsequently confirmed that, with the exception of ALL-8, glucocorticoid resistance in our xenografts could not be attributed to defects at the level of receptorligand interactions. The highly resistant xenograft, ALL-7, contained significantly higher numbers of GR binding sites per cell, consistent with the higher expression levels of GR protein evident by immunoblot analysis. These results were validated by radioligand binding studies using leukemia only.
For personal use at PENN STATE UNIVERSITY on February 20, 2013. bloodjournal.hematologylibrary.org From cells freshly harvested from the spleens of engrafted mice, which confirmed the comparable binding properties of two resistant xenografts (ALL-7 and -19) with the sensitive (ALL-3). These findings support the conclusion that, whilst common in laboratory-derived cell lines, 25,39,40 defects at the level of receptor-ligand interactions are unlikely to account for most instances of resistance observed in the primary disease.
Ligand-induced translocation of GR from the cytoplasm to the nucleus is a critical step in the pathway of glucocorticoid action, prior to activation/repression of gene transcription.
41,42
Expression of several proteins that function to tether the GR in the cytoplasm has previously been associated with glucocorticoid resistance in cell line models. Such proteins include the hsp90 protein that forms the major component of the multiprotein complex that retains the GR in its inactive conformation in the cytoplasm. 10, 11 In addition, interaction between the GR and 14-3-3 family proteins may also affect glucocorticoid signaling pathways. 43 In our entire panel of xenografts, no defects in ligand-induced GR nuclear translocation were apparent, and this was confirmed by two independent methods. These results indicate that the failure of the highly resistant xenografts to undergo apoptosis in response to dexamethasone is not a result of cytoplasmic retention of the GR. These observations are consistent with previous findings that failed to detect any correlation between hsp90 expression and glucocorticoid resistance in primary patient material.
44
Increased GR expression in response to glucocorticoid treatment has been documented in a number of cell lines and has been hypothesized to be necessary for induction of apoptosis in leukemia cells. 36 In non-lymphoid cell lines and lymphoblasts from healthy volunteers, GR downregulation is observed in response to glucocorticoid treatment. 45 It has been proposed that there is a T-cell specific promoter in the human GR gene that explains why T-lineage ALL cell lines, such as CEM cells, up-regulate GR in response to glucocorticoids, while BCP-ALL cell lines undergo ligand-induced GR down-regulation. 46 ,47 However, in the present study, the GR was downregulated in response to dexamethasone in 4/4 xenografts tested, one of which was a only.
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Glucocorticoid-induced apoptosis is mediated by the intrinsic apoptotic pathway, which involves loss of mitochondrial transmembrane potential, release of apoptotic factors from the mitochondria, and subsequent activation of effector caspases. The Bcl-2 family of proteins are key regulators of these mitochondrial-mediated apoptotic events. and staining with GR antibody. GR was detected using Cy3-labeled secondary antibody (red) and slides were counterstained with DAPI to indicate nuclei (blue). Images were captured using a fluorescent microscope equipped with a cooled CCD camera, under a 63x oil-immersion objective.
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